# HOPE: Olaparib, Palbociclib and Fulvestrant in Patients With BRCA Mutation-associated, HR+, HER2-metastatic Breast Cancer

> **NCT03685331** · PHASE1 · COMPLETED · sponsor: **Abramson Cancer Center at Penn Medicine** · enrollment: 9 (actual)

## Conditions studied

- Metastatic Breast Cancer
- Locally Advanced Breast Cancer
- Advanced Breast Cancer
- BRCA2 Mutation
- BRCA1 Mutation

## Interventions

- **DRUG:** Palbociclib
- **DRUG:** Olaparib
- **DRUG:** Fulvestrant

## Key facts

- **NCT ID:** NCT03685331
- **Lead sponsor:** Abramson Cancer Center at Penn Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-10-15
- **Primary completion:** 2025-08-01
- **Final completion:** 2025-12-01
- **Target enrollment:** 9 (ACTUAL)
- **Last updated:** 2026-01-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03685331

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03685331, "HOPE: Olaparib, Palbociclib and Fulvestrant in Patients With BRCA Mutation-associated, HR+, HER2-metastatic Breast Cancer". Retrieved via AI Analytics 2026-05-19 from https://api.ai-analytics.org/clinical/NCT03685331. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*